Last reviewed · How we verify
NCT02375958
PCA062 in pCAD-positive Tumors.
Completed
Phase 1
Last updated 19 December 2020
What this trial tests
Phase 1 trial testing PCA062 in Triple Negative Breast Cancer in 47 participants. Completed in 17 July 2018.
Timeline
15 April 2015
Primary endpoint
17 July 2018
17 July 2018
17 July 2018
Quick facts
| Lead sponsor | Novartis Pharmaceuticals |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 47 |
| Start date | 15 April 2015 |
| Primary completion | 17 July 2018 |
| Estimated completion | 17 July 2018 |
| Sites | 7 locations across France, Italy, Japan, Singapore, United States, Spain |
Drugs / interventions tested
- PCA062 — full drug profile →
Conditions studied
- Triple Negative Breast Cancer — all drugs for Triple Negative Breast Cancer →
- Head & Neck Cancer — all drugs for Head & Neck Cancer →
- Esophageal Cancer — all drugs for Esophageal Cancer →
Sponsor
Novartis Pharmaceuticals — full company profile →
Who can join
18 and older, any sex, with Triple Negative Breast Cancer or Head & Neck Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A first-in-human sttudy using PCA062 in patients with p-CAD positive solid tumors.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Cancer immunotherapy beyond immune checkpoint inhibitors.
Marin-Acevedo JA, Soyano AE, Dholaria B, Knutson KL, et al · · 2018 · cited 140× · PMID 29329556 · DOI 10.1186/s13045-017-0552-6 -
Breast Cancer Stem Cell Membrane Biomarkers: Therapy Targeting and Clinical Implications.
Conde I, Ribeiro AS, Paredes J. · · 2022 · cited 21× · PMID 35326385 · DOI 10.3390/cells11060934 -
Cadherin-3 is a novel oncogenic biomarker with prognostic value in glioblastoma.
Martins EP, Gonçalves CS, Pojo M, Carvalho R, et al · · 2022 · cited 14× · PMID 34919784 · DOI 10.1002/1878-0261.13162 -
A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody-Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors.
Duca M, Lim DW, Subbiah V, Takahashi S, et al · · 2022 · cited 13× · PMID 35131875 · DOI 10.1158/1535-7163.mct-21-0652 -
Molecular-targeted therapy toward precision medicine for gastrointestinal caner: Current progress and challenges.
Matsuoka T, Yashiro M. · · 2021 · cited 7× · PMID 34040699 · DOI 10.4251/wjgo.v13.i5.366 -
Preclinical Characterization of the Radioimmunoconjugate <sup>111</sup>In or <sup>90</sup>Y-FF-21101 Against a P-Cadherin-Expressing Tumor in a Mouse Xenograft Model and a Nonhuman Primate.
Funase Y, Nakamura E, Kajita M, Saito Y, et al · · 2021 · cited 6× · PMID 32737245 · DOI 10.2967/jnumed.120.245837 -
Dual blockage of P-cadherin and c-Met synergistically inhibits the growth of head and neck cancer.
Liu L, Oh C, Lim MA, Zheng S, et al · · 2025 · cited 1× · PMID 40392501 · DOI 10.1007/s13402-025-01061-w -
Antibody-drug conjugates in recurrent or metastatic HNSCC: relevant targets, clinical development, and future prospects.
Zhao H, Zhang S, Wang F, Yu P, et al · · 2026 · PMID 42254025 · DOI 10.3389/fimmu.2026.1828131
Verify or expand the search:
- PubMed search for NCT02375958
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Triple Negative Breast Cancer
Currently open trials in the same condition.
- NCT07533123 — A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who H · Phase 3 · recruiting
- NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
- NCT07340541 — Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies · Phase 2 · recruiting
- NCT07281976 — A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer · Phase 1, PHASE2 · recruiting
- NCT06225505 — Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE) · NA · recruiting
Other Novartis Pharmaceuticals trials
Trials by the same sponsor.
- NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
- NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
- NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
- NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
- NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT02375958 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
- Last refreshed: 19 December 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02375958.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing